DK2350078T3 - Forbindelser, der opformerer hæmatopoietiske stamceller - Google Patents

Forbindelser, der opformerer hæmatopoietiske stamceller Download PDF

Info

Publication number: DK2350078T3
Authority: DK; Denmark
Prior art keywords: humatopoitic; stamps; connections relating; relating; connections
Prior art date: 2008-10-30

Application number

DK09748626.0T

Other languages

English (en)

Inventor

Anthony Boitano

Michael Cooke

Shifeng Pan

Peter G Schultz

Yongqin Wan

Xing Wang

John TELLEW

Original Assignee

Novartis Ag

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-30

Filing date

2009-10-29

Publication date

2019-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2350078(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-29 Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag

2019-07-15 Application granted granted Critical

2019-07-15 Publication of DK2350078T3 publication Critical patent/DK2350078T3/da

Links

0 CCC1C(*C(C)[C@@](C)*)C1C*N(C)C Chemical compound CCC1C(*C(C)[C@@](C)*)C1C*N(C)C 0.000 description 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK09748626.0T 2008-10-30 2009-10-29 Forbindelser, der opformerer hæmatopoietiske stamceller DK2350078T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10982108P	2008-10-30	2008-10-30
US24276509P	2009-09-15	2009-09-15
PCT/US2009/062646 WO2010059401A2 (en)	2008-10-30	2009-10-29	Compounds that expand hematopoietic stem cells

Publications (1)

Publication Number	Publication Date
DK2350078T3 true DK2350078T3 (da)	2019-07-15

Family

ID=42111339

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09748626.0T DK2350078T3 (da)	2008-10-30	2009-10-29	Forbindelser, der opformerer hæmatopoietiske stamceller

Country Status (41)

Country	Link
US (4)	US8927281B2 (da)
EP (2)	EP2350078B1 (da)
JP (1)	JP5390626B2 (da)
KR (1)	KR101434719B1 (da)
CN (1)	CN102203096B (da)
AR (1)	AR074063A1 (da)
AU (1)	AU2009317898B2 (da)
BR (1)	BRPI0921799B8 (da)
CA (3)	CA2740589C (da)
CL (2)	CL2009002010A1 (da)
CO (1)	CO6410309A2 (da)
CR (1)	CR20110192A (da)
CU (1)	CU24495B1 (da)
CY (1)	CY1121857T1 (da)
DK (1)	DK2350078T3 (da)
DO (1)	DOP2011000114A (da)
EA (1)	EA019872B1 (da)
EC (1)	ECSP11011090A (da)
ES (2)	ES2948567T3 (da)
GE (1)	GEP20146053B (da)
HN (1)	HN2011001195A (da)
HR (1)	HRP20191238T1 (da)
HU (1)	HUE044802T2 (da)
IL (1)	IL212368A (da)
JO (1)	JO3593B1 (da)
LT (1)	LT2350078T (da)
MA (1)	MA32828B1 (da)
MX (1)	MX347834B (da)
MY (1)	MY155137A (da)
NI (1)	NI201100083A (da)
NZ (1)	NZ592435A (da)
PE (1)	PE20100362A1 (da)
PL (1)	PL2350078T3 (da)
PT (1)	PT2350078T (da)
RS (1)	RS59027B1 (da)
SI (1)	SI2350078T1 (da)
SM (1)	SMP201100024B (da)
SV (1)	SV2011003888A (da)
TN (1)	TN2011000174A1 (da)
TW (1)	TWI532486B (da)
WO (1)	WO2010059401A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8846393B2 (en) *	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
WO2008116912A2 (en) *	2007-03-28	2008-10-02	Neurosearch A/S	Purinyl derivatives and their use as potassium channel modulators
KR101564233B1 (ko) *	2007-03-28	2015-10-29	뉴로서치 에이/에스	푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
KR20110042153A (ko) *	2008-05-30	2011-04-25	제넨테크, 인크.	퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
US20110237607A1 (en) *	2008-09-26	2011-09-29	Neurosearch A/S	Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) *	2008-09-26	2010-04-01	Neurosearch A/S	Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) *	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
WO2012074068A1 (ja)	2010-12-01	2012-06-07	日産化学工業株式会社	ピラゾール化合物による造血幹細胞の製造方法
WO2012102937A2 (en) *	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
US9353115B2 (en)	2011-06-01	2016-05-31	Janus Biotherapeutics, Inc.	Immune system modulators
US20140205582A1 (en) *	2011-07-06	2014-07-24	Cellerant Therapeutics, Inc.	Megakaryocyte progenitor cells for production of platelets
WO2013019857A2 (en) *	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
AU2012306285B2 (en) *	2011-09-07	2017-05-18	Deutsches Krebsforschungszentrum	Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
AU2012347534B2 (en) *	2011-12-08	2018-01-25	Fred Hutchinson Cancer Research Center	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
DK2807165T3 (da) *	2012-01-27	2019-07-15	Univ Montreal	Pyrimido[4,5-b]indol-derivater og anvendelse deraf i ekspansionen af hæmatopoietiske stamceller
AU2013219945B2 (en)	2012-02-13	2017-12-07	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
WO2014001282A1 (en)	2012-06-26	2014-01-03	Aniona Aps	A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) *	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
US9074186B2 (en) *	2012-08-15	2015-07-07	Boston Medical Center Corporation	Production of red blood cells and platelets from stem cells
US9956249B2 (en)	2013-01-08	2018-05-01	Fred Hutchinson Cancer Research Center	Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014138485A1 (en)	2013-03-08	2014-09-12	Irm Llc	Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CA2848575C (en) *	2013-05-17	2021-01-26	Universite De Montreal	Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
EP3060670B1 (en) *	2013-10-24	2019-07-10	Ospedale San Raffaele S.r.l.	Method
NZ719840A (en)	2013-10-31	2023-01-27	Seattle Children’S Hospital Dba Seattle Children’S Res Institute	Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
EP3247808B1 (en)	2015-01-21	2021-05-05	Fred Hutchinson Cancer Research Center	Point-of-care and/or portable platform for gene therapy
EP3995142A3 (en)	2015-04-29	2022-08-24	Fred Hutchinson Cancer Center	Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016176652A2 (en)	2015-04-29	2016-11-03	Fred Hutchinson Cancer Research Center	Modified stem cells and uses thereof
EP3362075B1 (en) *	2015-10-15	2023-06-07	Celularity Inc.	Natural killer cells and ilc3 cells and uses thereof
CN115927191A (zh)	2015-10-23	2023-04-07	优瑞科生物技术公司	抗体/t细胞受体嵌合构建体及其用途
US11154573B2 (en)	2015-10-30	2021-10-26	The Regents Of The University Of California	Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
IL260257B2 (en) *	2015-12-28	2024-05-01	Novartis Ag	Preparations and methods for the treatment of hemoglobinopathies
CR20180503A (es)	2016-04-14	2018-12-21	Hutchinson Fred Cancer Res	Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
SG11201809858RA (en) *	2016-05-07	2018-12-28	Celularity Inc	Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
JP6964096B2 (ja)	2016-05-25	2021-11-10	バイエルファーマアクチエンゲゼルシャフト	３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類
WO2018013430A2 (en)	2016-07-12	2018-01-18	Arisan Therapeutics Inc.	Heterocyclic compounds for the treatment of arenavirus infection
CN109890805B (zh) *	2016-08-18	2023-04-04	新加坡国立大学	用于造血干细胞和祖细胞的产生、增殖和分化的取代的唑衍生物
WO2018064387A1 (en)	2016-09-28	2018-04-05	Novartis Ag	Porous membrane-based macromolecule delivery system
TW201839136A (zh)	2017-02-06	2018-11-01	瑞士商諾華公司	治療血色素異常症之組合物及方法
JOP20190193A1 (ar)	2017-02-09	2019-08-08	Bayer Pharma AG	ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
JP7352807B2 (ja)	2017-04-12	2023-09-29	マジェンタセラピューティクスインコーポレイテッド	アリール炭化水素受容体アンタゴニスト及びその使用
EP3612030A4 (en) *	2017-04-21	2021-04-28	Ikena Oncology, Inc.	AHR INDOLE INHIBITORS AND THEIR USES
IL310182A (en)	2017-04-26	2024-03-01	Eureka Therapeutics Inc ׂ A Delaware Corp	Structures of chimeric antibody/T-cell receptor and uses thereof
US11548867B2 (en)	2017-07-19	2023-01-10	Idea Ya Biosciences, Inc.	Amido compounds as AhR modulators
JP2020529975A (ja)	2017-07-31	2020-10-15	ノバルティスアーゲー	コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
WO2019027765A1 (en) *	2017-08-02	2019-02-07	Northwestern University	SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
WO2019067792A1 (en)	2017-09-28	2019-04-04	Celularity, Inc.	TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
KR20200074134A (ko)	2017-09-29	2020-06-24	인텔리아 테라퓨틱스, 인크.	지질 나노파티클을 이용한 mRNA 전달의 체외 방법
CA3079405A1 (en)	2017-10-31	2019-05-09	Magenta Therapeutics Inc.	Compositions and methods for the expansion of hematopoietic stem and progenitor cells
CA3079404A1 (en)	2017-10-31	2019-05-09	Magenta Therapeutics Inc.	Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11591311B2 (en)	2017-11-21	2023-02-28	Bayer Aktiengesellschaft	3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11524944B2 (en)	2017-11-21	2022-12-13	Bayer Aktiengesellschaft	2-phenylpyrimidine-4-carboxamides as AHR inhibitors
US11459312B2 (en)	2017-11-21	2022-10-04	Bayer Aktiengesellschaft	Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CA3082855A1 (en)	2017-11-21	2019-05-31	Bayer Aktiengesellschaft	2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
WO2019113375A2 (en)	2017-12-06	2019-06-13	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) *	2018-01-03	2019-07-11	Magenta Therapeutics Inc.	Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US11530220B2 (en)	2018-02-06	2022-12-20	Ideaya Biosciences, Inc.	Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
WO2020018848A1 (en) *	2018-07-19	2020-01-23	Ideaya Biosciences, Inc.	Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
EP3841102B1 (en) *	2018-08-24	2022-09-14	Jaguahr Therapeutics Pte Ltd	Tetrahydropyridopyrimidine derivatives as ahr modulators
EP3843853A1 (en)	2018-08-31	2021-07-07	Jaguahr Therapeutics Pte Ltd	Heterocyclic compounds as ahr modulators
WO2020050409A1 (en)	2018-09-07	2020-03-12	Otsuka Pharmaceutical Co., Ltd.	Heterocyclic compound
US20220098613A1 (en)	2018-09-12	2022-03-31	Fred Hutchinson Cancer Research Center	Reducing cd33 expression to selectively protect therapeutic cells
CN113272305A (zh) *	2018-10-16	2021-08-17	医肯纳肿瘤学公司	吲哚ahr抑制剂及其用途
JP2022505615A (ja) *	2018-10-31	2022-01-14	マジェンタセラピューティクスインコーポレイテッド	造血幹・前駆細胞移植療法の方法
BR112022001628A2 (pt) *	2019-08-12	2022-06-21	Bayer Ag	[1,2,4]triazolo[1,5-c]quinazolin-5-aminas
EP4051298A1 (en)	2019-11-01	2022-09-07	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CN115279764A (zh)	2019-11-26	2022-11-01	医肯纳肿瘤学公司	多晶型咔唑衍生物及其用途
CN114667280A (zh)	2019-12-09	2022-06-24	大塚制药株式会社	丙烯酰胺化合物
JP2023506842A (ja)	2019-12-18	2023-02-20	ノバルティスアーゲー	異常ヘモグロビン症の治療用組成物及び方法
WO2021173082A1 (en)	2020-02-26	2021-09-02	Jaguahr Therapeutics Pte Ltd	Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN115715203A (zh)	2020-05-06	2023-02-24	塞勒克提斯公司	对细胞进行基因修饰以递送治疗性蛋白质的方法
CA3177093A1 (en)	2020-05-06	2021-11-11	Cellectis S.A.	Methods for targeted insertion of exogenous sequences in cellular genomes
WO2021224633A1 (en)	2020-05-06	2021-11-11	Orchard Therapeutics (Europe) Limited	Treatment for neurodegenerative diseases
JP7215776B2 (ja)	2020-07-01	2023-01-31	ネクスジェン株式会社	ヒト長期造血幹細胞マーカー
WO2022029063A1 (en)	2020-08-04	2022-02-10	Bayer Aktiengesellschaft	Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114369097B (zh) *	2020-10-15	2023-07-14	山东轩竹医药科技有限公司	杂芳环类AhR抑制剂
WO2022197776A1 (en)	2021-03-16	2022-09-22	Magenta Therapeutics, Inc.	Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2022269518A2 (en)	2021-06-23	2022-12-29	Novartis Ag	Compositions and methods for the treatment of hemoglobinopathies
WO2023150393A2 (en)	2022-02-07	2023-08-10	Ensoma, Inc.	Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
WO2024020429A1 (en)	2022-07-22	2024-01-25	Lyell Immunopharma, Inc.	Immune cell therapy
WO2024076300A1 (en)	2022-10-03	2024-04-11	Jaguahr Therapeutics Pte Ltd	Compounds useful in modulation of ahr signalling

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3399196A (en)	1959-01-22	1968-08-27	Ciba Geigy Corp	Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de)	1981-12-19	1983-08-25	Merck Patent Gmbh, 6100 Darmstadt	Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) *	1989-06-15	1995-08-01	Regents Of The University Of Michigan	Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en)	1990-11-08	1992-06-02	Whitby Research, Inc.	Method of determining viability of tissue
EP0682027B1 (de) *	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
FR2732604B1 (fr) *	1995-04-07	1997-06-06	Vacsyn Sa	Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr)	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) *	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
JP2002529502A (ja)	1998-11-17	2002-09-10	スミスクライン・ビーチャム・コーポレイション	血小板減少症の治療法
GC0000177A (en)	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
RU2001124352A (ru) *	1999-02-01	2004-02-20	Си Ви Терапьютикс, Инк. (Us)	Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
WO2000066112A1 (en)	1999-05-03	2000-11-09	Smithkline Beecham Corporation	Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6960439B2 (en) *	1999-06-28	2005-11-01	Source Precision Medicine, Inc.	Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh)	1999-07-13	2003-06-04	中国人民解放军第二军医大学	一种体外扩增造血干细胞的新方法
EP1213965B1 (en)	1999-09-10	2006-01-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
ATE350044T1 (de)	1999-09-24	2007-01-15	Smithkline Beecham Corp	Thrombopoietinmimetika
AU1462201A (en)	1999-11-05	2001-06-06	Smithkline Beecham Corporation	Semicarbazone derivatives and their use as thrombopoietin mimetics
JP2003515560A (ja)	1999-12-06	2003-05-07	スミスクライン・ビーチャム・コーポレイション	トロンボポイエチン模倣物
DE60028253T2 (de)	1999-12-17	2007-03-08	Ariad Pharmaceuticals, Inc., Cambridge	Neue purine
CA2396276A1 (en)	2000-01-07	2001-07-12	Universitaire Instelling Antwerpen	Purine derivatives, process for their preparation and use thereof
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
AU7107301A (en) *	2000-07-18	2002-01-30	Nichimo Co. Ltd.	Stem cell reinforcing material
CA2436288A1 (en)	2000-12-19	2002-06-27	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1370252A4 (en)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
WO2003031406A2 (en) *	2001-10-12	2003-04-17	Irm Llc	Kinase inhibitor scaffolds and methods for their preparation
BR0207725A (pt) *	2001-12-28	2004-03-23	Daiichi Suntory Biomedical Res	Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
JP4562523B2 (ja)	2002-06-06	2010-10-13	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	トロンボポエチン疑似体
US20030139427A1 (en) *	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) *	2002-08-30	2004-03-25	Kobe University	Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
WO2004054515A2 (en)	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Thrombopoietin mimetics
WO2005020892A2 (en) *	2003-08-08	2005-03-10	Mitochroma Research, Inc.	Pharmaceutical compositions and methods for metabolic modulation
EP1670795A1 (en) *	2003-09-18	2006-06-21	ALTANA Pharma AG	Pharmacologically active imidazo 4,5-c pyridines
CA2548951A1 (en)	2003-12-22	2005-07-14	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
TW200538120A (en)	2004-02-20	2005-12-01	Kirin Brewery	Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US7622108B2 (en) *	2004-04-23	2009-11-24	Bioe, Inc.	Multi-lineage progenitor cells
ZA200701781B (en) *	2004-09-03	2008-11-26	Prometic Biosciences Inc	Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
GB0420719D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
AR052771A1 (es) *	2004-09-30	2007-04-04	Tibotec Pharm Ltd	Pirimidinas biciclicas inhibidoras del vhc
FR2876583B1 (fr)	2004-10-15	2007-04-13	Centre Nat Rech Scient Cnrse	Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006061380A2 (en)	2004-12-09	2006-06-15	Altana Pharma Ag	SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
WO2006118914A2 (en) *	2005-04-29	2006-11-09	Children's Medical Center Corporation	Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
PL1910338T3 (pl)	2005-07-14	2011-02-28	Irm Llc	Związki heterotetracykliczne jako mimetyki TPO
EP1915341A2 (en)	2005-08-15	2008-04-30	Irm, Llc	Compounds and compositions as tpo mimetics
US8258141B2 (en) *	2006-04-21	2012-09-04	Novartis Ag	Organic compounds
RU2009100930A (ru)	2006-06-14	2010-07-20	Чугаи Сейяку Кабусики Кайся (Jp)	Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
WO2007149548A2 (en) *	2006-06-22	2007-12-27	Medistem Laboratories, Inc.	Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (en) *	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
WO2008028645A1 (en)	2006-09-05	2008-03-13	Aplagen Gmbh	Peptides binding the tpo receptor
WO2008051502A1 (en)	2006-10-19	2008-05-02	Genzyme Corporation	Purine derivatives for the treatment of cystic diseases
US9394520B2 (en)	2006-12-08	2016-07-19	University Of Rochester	Expansion of hematopoietic stem cells
WO2008116912A2 (en) *	2007-03-28	2008-10-02	Neurosearch A/S	Purinyl derivatives and their use as potassium channel modulators
EP2252616B1 (en) *	2008-01-30	2014-07-23	Genentech, Inc.	Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
PE20100362A1 (es) *	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) *	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity

2009
- 2009-10-27 PE PE2009001206A patent/PE20100362A1/es active IP Right Grant
- 2009-10-28 AR ARP090104145A patent/AR074063A1/es active IP Right Grant
- 2009-10-29 ES ES19164770T patent/ES2948567T3/es active Active
- 2009-10-29 EA EA201100663A patent/EA019872B1/ru not_active IP Right Cessation
- 2009-10-29 ES ES09748626T patent/ES2736728T3/es active Active
- 2009-10-29 CA CA2740589A patent/CA2740589C/en active Active
- 2009-10-29 DK DK09748626.0T patent/DK2350078T3/da active
- 2009-10-29 HU HUE09748626 patent/HUE044802T2/hu unknown
- 2009-10-29 US US12/608,946 patent/US8927281B2/en active Active
- 2009-10-29 SI SI200931987T patent/SI2350078T1/sl unknown
- 2009-10-29 GE GEAP200912209A patent/GEP20146053B/en unknown
- 2009-10-29 RS RS20190863A patent/RS59027B1/sr unknown
- 2009-10-29 TW TW098136716A patent/TWI532486B/zh active
- 2009-10-29 CN CN200980143651.3A patent/CN102203096B/zh active Active
- 2009-10-29 JO JOP/2009/0399A patent/JO3593B1/ar active
- 2009-10-29 PL PL09748626T patent/PL2350078T3/pl unknown
- 2009-10-29 MY MYPI2011001595A patent/MY155137A/en unknown
- 2009-10-29 CU CU2011000096A patent/CU24495B1/es unknown
- 2009-10-29 MX MX2011004593A patent/MX347834B/es active IP Right Grant
- 2009-10-29 KR KR1020117012091A patent/KR101434719B1/ko active IP Right Grant
- 2009-10-29 EP EP09748626.0A patent/EP2350078B1/en active Active
- 2009-10-29 LT LTEP09748626.0T patent/LT2350078T/lt unknown
- 2009-10-29 JP JP2011534784A patent/JP5390626B2/ja active Active
- 2009-10-29 BR BRPI0921799A patent/BRPI0921799B8/pt active IP Right Grant
- 2009-10-29 AU AU2009317898A patent/AU2009317898B2/en not_active Ceased
- 2009-10-29 WO PCT/US2009/062646 patent/WO2010059401A2/en active Application Filing
- 2009-10-29 CA CA2943540A patent/CA2943540C/en active Active
- 2009-10-29 PT PT09748626T patent/PT2350078T/pt unknown
- 2009-10-29 CA CA3061937A patent/CA3061937A1/en not_active Abandoned
- 2009-10-29 NZ NZ592435A patent/NZ592435A/xx unknown
- 2009-10-29 EP EP19164770.0A patent/EP3524604B1/en active Active
- 2009-10-30 CL CL2009002010A patent/CL2009002010A1/es unknown
2011
- 2011-04-13 TN TN2011000174A patent/TN2011000174A1/fr unknown
- 2011-04-14 CR CR20110192A patent/CR20110192A/es unknown
- 2011-04-14 IL IL212368A patent/IL212368A/en active IP Right Grant
- 2011-04-27 SV SV2011003888A patent/SV2011003888A/es unknown
- 2011-04-28 DO DO2011000114A patent/DOP2011000114A/es unknown
- 2011-04-28 HN HN2011001195A patent/HN2011001195A/es unknown
- 2011-04-29 NI NI201100083A patent/NI201100083A/es unknown
- 2011-05-11 CO CO11058070A patent/CO6410309A2/es not_active Application Discontinuation
- 2011-05-13 SM SM201100024T patent/SMP201100024B/it unknown
- 2011-05-25 MA MA33889A patent/MA32828B1/fr unknown
- 2011-05-30 EC EC2011011090A patent/ECSP11011090A/es unknown
2013
- 2013-04-05 US US13/857,939 patent/US9580426B2/en active Active
- 2013-06-24 CL CL2013001874A patent/CL2013001874A1/es unknown
2017
- 2017-01-18 US US15/409,292 patent/US20170239296A1/en not_active Abandoned
2019
- 2019-07-10 HR HRP20191238 patent/HRP20191238T1/hr unknown
- 2019-07-17 CY CY20191100765T patent/CY1121857T1/el unknown
2020
- 2020-11-06 US US17/092,107 patent/US20210187033A1/en not_active Abandoned

Also Published As

Publication number	Publication date
LT2350078T (lt)	2019-07-25
CL2013001874A1 (es)	2014-04-04
ECSP11011090A (es)	2011-09-30
AR074063A1 (es)	2010-12-22
AU2009317898A1 (en)	2010-05-27
CN102203096B (zh)	2014-09-17
CN102203096A (zh)	2011-09-28
US20210187033A1 (en)	2021-06-24
EP3524604A1 (en)	2019-08-14
JO3593B1 (ar)	2020-07-05
US20140114070A1 (en)	2014-04-24
CU24495B1 (es)	2021-01-12
CA2943540A1 (en)	2010-05-27
SMAP201100024A (it)	2011-07-11
US20100183564A1 (en)	2010-07-22
PE20100362A1 (es)	2010-05-27
PT2350078T (pt)	2019-07-19
CO6410309A2 (es)	2012-03-30
SV2011003888A (es)	2011-07-05
CR20110192A (es)	2011-06-10
EP2350078A2 (en)	2011-08-03
DOP2011000114A (es)	2017-09-29
EA019872B1 (ru)	2014-06-30
IL212368A (en)	2015-02-26
ES2948567T3 (es)	2023-09-14
NZ592435A (en)	2013-01-25
EP3524604B1 (en)	2023-03-29
US8927281B2 (en)	2015-01-06
MA32828B1 (fr)	2011-11-01
TN2011000174A1 (en)	2012-12-17
TW201028153A (en)	2010-08-01
HRP20191238T1 (hr)	2019-11-29
SI2350078T1 (sl)	2019-08-30
AU2009317898B2 (en)	2013-07-11
BRPI0921799B8 (pt)	2021-05-25
WO2010059401A3 (en)	2010-09-23
US9580426B2 (en)	2017-02-28
EP2350078B1 (en)	2019-04-17
CA3061937A1 (en)	2010-05-27
CA2943540C (en)	2020-10-27
IL212368A0 (en)	2011-06-30
US20170239296A1 (en)	2017-08-24
KR20110075042A (ko)	2011-07-05
RS59027B1 (sr)	2019-08-30
WO2010059401A2 (en)	2010-05-27
JP2012507554A (ja)	2012-03-29
CU20110096A7 (es)	2012-01-31
SMP201100024B (it)	2012-03-05
MX347834B (es)	2016-10-07
CY1121857T1 (el)	2020-07-31
JP5390626B2 (ja)	2014-01-15
BRPI0921799A2 (pt)	2016-01-12
HUE044802T2 (hu)	2019-11-28
BRPI0921799B1 (pt)	2020-09-29
EA201100663A1 (ru)	2011-12-30
ES2736728T3 (es)	2020-01-07
KR101434719B1 (ko)	2014-08-27
HN2011001195A (es)	2014-01-13
MY155137A (en)	2015-09-15
GEP20146053B (en)	2014-03-10
TWI532486B (zh)	2016-05-11
MX2011004593A (es)	2011-06-16
CA2740589A1 (en)	2010-05-27
CL2009002010A1 (es)	2010-06-25
NI201100083A (es)	2011-11-03
CA2740589C (en)	2017-11-21
PL2350078T3 (pl)	2019-09-30

Publication	Publication Date	Title
DK2350078T3 (da)	2019-07-15	Forbindelser, der opformerer hæmatopoietiske stamceller
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
SE0850083L (sv)	2010-05-20	Funktionell inkapsling
DE602008002756D1 (de)	2010-11-04	Bauzusammensetzung
DK2315696T3 (da)	2013-07-08	Cykel
BRPI0906749A2 (pt)	2015-07-07	Composição
BRPI0913808A2 (pt)	2017-06-20	composição
IT1392848B1 (it)	2012-03-23	Motociclo.
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
BRPI0917231A2 (pt)	2015-11-10	composição
BRPI0915524A2 (pt)	2016-01-26	conjunto de aerofólio
DE602009000049D1 (de)	2010-08-12	Motorrad
DE602009001140D1 (de)	2011-06-09	Motorrad
IT1393579B1 (it)	2012-04-27	Motociclo.
FI20080146A0 (fi)	2008-02-22	Liiskauspuristin
DE602008001961D1 (de)	2010-09-09	Motorrad
BRPI0914664A2 (pt)	2015-10-20	motocicleta
DE602009000236D1 (de)	2010-11-11	Motorrad
DE602009000066D1 (de)	2010-09-02	Motorrad
DK2379722T3 (da)	2017-01-02	Ekspressionsvektor
BRPI0917584A2 (pt)	2015-11-17	composição
UA18933S (uk)	2009-05-25	Скутер
BRPI0920692A2 (pt)	2015-12-29	composição
FI20080325A (fi)	2009-10-31	Pihkaliuos
MA31558B1 (fr)	2010-08-02	Arriere-plan technologique